Domain Therapeutics (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Domain Therapeutics

#biopharma #biotech #drugdiscovery #GPCR #Immunooncology #immunosuppression

Founded 2008 France

France 88 employees Grant Total: $90.04M Biotechnology, Health Care +2

Domain Therapeutics is a clinical-stage global biopharmaceutical company founded in 2001, headquartered in France. The company is focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), which are crucial in drug discovery. Domain Therapeutics aims to unlock new possibilities in cancer by approaching it differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. With two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, the company has established itself as a leader in GPCRs in immuno-oncology. The company's proprietary programs, including DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, DT-9081, an EP4 receptor antagonist, and M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA, demonstrate its commitment to delivering innovative immunotherapies to patients. Domain Therapeutics also maintains an optimized pipeline of best-in-class and first-in-class GPCR targets selected through its proprietary cross-validation drug discovery and development platform. The company recently received a €10.00M grant investment on 25 January 2024 from Agence National de la Recherche, further affirming its position in the biotechnology, healthcare, and pharmaceutical industries. With its focused approach and solid partnerships, Domain Therapeutics is poised to make significant contributions to the field of cancer immunotherapy.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	••••••	1	•••• ••••	25 Jan 2024
Series A	••••••	10	•••• ••••	10 May 2022
Debt Financing	••••••	4	•••• ••••	13 Jan 2020
Venture Round	••••••	1		28 May 2019
Grant	••••••	1		14 Apr 2014

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

••••••

•••• ••••

25 Jan 2024

Series A

••••••

•••• ••••

10 May 2022

Debt Financing

••••••

•••• ••••

13 Jan 2020

Venture Round

••••••

28 May 2019

Grant

••••••

14 Apr 2014

FAQ About Domain Therapeutics

#biopharma #biotech #drugdiscovery #GPCR #Immunooncology #immunosuppression

Domain Therapeutics was founded in 2008.

Domain Therapeutics is headquartered in France.

Domain Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness, Pharmaceutical.

Domain Therapeutics has approximately 88 employees.

Domain Therapeutics has completed 10 funding rounds, raising a total of $90.04M. The latest funding stage is Grant.

Top alternatives and competitors to Domain Therapeutics include INVENT Pharmaceuticals, Mebias Discovery, Inc, Design Pharmaceuticals Inc., AlphaMol Science Ltd, Helicore Biopharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Domain Therapeutics and INVENT Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Domain Therapeutics

General Information

Track Domain Therapeutics

Discover More

About Domain Therapeutics

Funding Rounds & Investors (10)

Domain Therapeutics Alternatives & Competitors

FAQ About Domain Therapeutics

Don't just browse. Track.